CRPPA: A Potential Drug Target and Biomarker for Various Diseases

Target Name: CRPPA

NCBI ID: G729920

CRPPA

CRPPA: A Potential Drug Target and Biomarker for Various Diseases

CRPPA (Complement receptor protein-alpha) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the complement receptor protein family, which includes proteins that are involved in the immune response and inflammation.

Recent studies have identified CRPPA as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the recent studies on CRPPA and its potential as a drug target and biomarker.

Potential Drug Target

CRPPA has been identified as a potential drug target for various diseases due to its unique structure and its involvement in the immune response. One of the main reasons for its potential as a drug target is its expression in various tissues, including the brain, which suggests that it may be involved in the development and progression of certain diseases.

Studies have shown that CRPPA is highly expressed in the brains of individuals with Alzheimer's disease, which is a neurodegenerative disease that is characterized by the progressive loss of brain cells. Therefore, researchers have been investigating the potential role of CRPPA in the development and progression of Alzheimer's disease.

In addition, CRPPA has also been shown to be highly expressed in the lungs of individuals with chronic obstructive pulmonary disease (COPD), which is a progressive lung disease that is associated with chronic inflammation. Therefore, researchers have been investigating the potential role of CRPPA in the development and progression of COPD.

Potential Biomarker

In addition to its potential as a drug target, CRPPA has also been identified as a potential biomarker for various diseases. Studies have shown that CRPPA levels are elevated in individuals with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main reasons for its potential as a biomarker is its stability and its ability to be detected in various biological samples, including blood, urine, and tissue. This makes it a potential biomarker for a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that CRPPA levels are elevated in individuals with various types of cancer, including breast, lung, and ovarian cancer. Therefore, CRPPA may be a potential biomarker for cancer.

In addition, CRPPA levels have also been shown to be elevated in individuals with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, CRPPA may be a potential biomarker for neurodegenerative diseases.

In addition, CRPPA levels have also been shown to be elevated in individuals with autoimmune disorders, including rheumatoid arthritis and psoriasis. Therefore, CRPPA may be a potential biomarker for autoimmune disorders.

Conclusion

In conclusion, CRPPA is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and its involvement in the immune response make it a promising target for the development of new treatments for a wide range of diseases.

While further research is needed to fully understand the role of CRPPA as a drug target and biomarker, its potential as a new treatment option for a wide range of diseases is clear. As research continues to progress, we can expect to see new studies emerge that will further clarify the role of CRPPA in the development and treatment of various diseases.

Protein Name: CDP-L-ribitol Pyrophosphorylase A

Functions: Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:27130732, PubMed:27601598, PubMed:26687144, PubMed:22522421, PubMed:26923585). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:27130732, PubMed:26687144, PubMed:26923585). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular proteins with high affinity (PubMed:27130732, PubMed:26687144, PubMed:26923585). Shows activity toward other pentose phosphate sugars and mediates formation of CDP-ribulose or CDP-ribose using CTP and ribulose-5-phosphate or ribose-5-phosphate, respectively (PubMed:26687144). Not Involved in dolichol production (PubMed:26687144)

The "CRPPA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRPPA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets